Genetics of Parkinson's disease: The yield

Parkinsonism and Related Disorders

Volumn 20, Issue SUPPL.1, 2014, Pages

  Spatola, Marianna ^a   Wider, Christian ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Molecular mechanisms; Monogenic forms; Parkinson; Risk genes

Indexed keywords

ALPHA SYNUCLEIN; DJ 1 PROTEIN; LEUCINE RICH REPEAT KINASE 2; LEVODOPA;

ARTICLE; DJ 1 GENE; EIF4G1 GENE; GBA GENE; GENE; GENE INTERACTION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; LRRK2 GENE; MUTATIONAL ANALYSIS; NONHUMAN; PARK2 GENE; PARKINSON DISEASE; PARKINSONISM; PHENOTYPE; PINK1 GENE; PRIORITY JOURNAL; RISK FACTOR; SMPD1 GENE; SNCA GENE; VPS35 GENE;

MOLECULAR MECHANISMS; MONOGENIC FORMS; PARKINSON; RISK GENES;

GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PARKINSON DISEASE; RISK FACTORS;

EID: 84887934289     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/S1353-8020(13)70011-7     Document Type: Article

References (30)

1. Cookson MR The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 2010, 11(12):791-797.
2. Ross OA, Soto-Ortolaza AI, Heckman MG, Aasly JO, Abahuni N, Annesi G, et al. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol 2011, 10:898-908.
3. Marras C, Schüle B, Munhoz RP, Rogaeva E, Langston JW, Kasten M, et al. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology 2011, 77(4):325-333.
4. Saunders-Pullman R, Stanley K, Wang C, San Luciano M, Shanker V, Hunt A, et al. Olfactory dysfunction in LRRK2 G2019S mutation carriers. Neurology 2011, 77:319-324.
5. Mirelman A, Gurevich T, Giladi N, Bar-Shira A, Orr-Urtreger A, Hausdorff JM Gait alterations in healthy carriers of the LRRK2 G2019S mutation. Ann Neurol 2011, 69:193-197.
6. Wider C, Dickson DW, Wszolek ZK Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation. Neurodegener Dis 2010, 7:175-179.
7. Vilariño-Güell C, Wider C, Ross OA, Dachsel JC, Kachergus JM, Lincoln SJ, et al. VPS35 mutations in Parkinson disease. Am J Hum Genet 2011, 89(1):162-167.
8. Zimprich A, Benet-Pagès A, Struhal W, Graf E, Eck SH, Offman MN, et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet 2011, 89(1):168-175.
9. Kumar KR, Weissbach A, Heldmann M, Kasten M, Tunc S, Sue CM, et al. Frequency of the D620N mutation in VPS35 in Parkinson disease. Arch Neurol 2012, 69(10):1360-1364.
10. Chartier-Harlin MC, Dachsel JC, Vilarino-Guell C, Lincoln SJ, Lepretre F, Hulihan MM, et al. Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet 2011, 89:398-406.
11. Tucci A, Charlesworth G, Sheerin UM, Plagnol V, Wood NW, Hardy J Study of the genetic variability in a Parkinson's disease gene: EIF4G1. Neurosci Lett 2012, 518:19-22.
12. Schulte EC, Mollenhauer B, Zimprich A, Bereznai B, Lichtner P, Haubenberger D, et al. Variants in eukaryotic translation initiation factor 4G1 in sporadic Parkinson's disease. Neurogenetics 2012, 13:281-285.
13. Lohmann E, Periquet M, Bonifati V, Wood NW, De Michele G, Bonnet AM, et al. How much phenotypic variation can be attributed to parkin genotype?. Ann Neurol 2003, 54:176-185.
14. Lai HJ, Lin CH, Wu RM Early-onset autosomal-recessive parkinsonian-pyramidal syndrome. Acta Neurol Taiwan 2012, 21(3):99-107.
15. Khateeb S, Flusser H, Ofir R, Shelef I, Narkis G, Vardi G, et al. PLA2G6 mutation underlies infantile neuroaxonal dystrophy. Am J Hum Genet 2006, 79:942-948.
16. Morgan NV, Westaway SK, Morton JE, Gregory A, Gissen P, Sonek S, et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet 2006, 38:752-754.
17. Paisan-Ruiz C, Bhatia KP, Li A, Hernandez D, Davis M, Wood NW, et al. Characterization of PLA2G6 as a locus for dystonia parkinsonism. Ann Neurol 2009, 65:19-23.
18. Usenovic M, Knight AL, Ray A, Wong V, Brown KR, Caldwell GA, et al. Identification of novel ATP13A2 interactors and their role in alpha-synuclein misfolding and toxicity. Hum Mol Genet 2012, 21:3785-3794.
19. Ho MS, Ou C, Chan YR, Chien CT, Pi H The utility F-box for protein destruction. Cell Mol Life Sci 2008, 65:1977-2000.
20. Balsinde J, Balboa MA Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A2 in activated cells. Cell Signal 2005, 17:1052-1062.
21. Edvardson S, Cinnamon Y, Ta-Shma A, Shaag A, Yim YI, Zenvirt S, et al. A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism. PLoS One 2012, 7(5):e36458.
22. UK Parkinson's Disease Consortium, Wellcome Trust Case Control Consortium 2, Spencer CC, Plagnol V, Strange A, Gardner M, Paisan-Ruiz C, Band G, et al. Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet 2011, 20(2):345-353.
23. Bonifati V LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson's disease. Neurochem Res 2007, 32:1700-1708.
24. Maraganore DM, de Andrade M, Elbaz A, Farrer MJ, Ioannidis JP, Krüger R, et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 2006, 296(6):661-670.
25. Wider C, Vilariño-Güell C, Jasinska-Myga B, Heckman MG, Soto-Ortolaza AI, Cobb SA, et al. Association of the MAPT locus with Parkinson's disease. Eur J Neurol 2010, 17(3):483-486.
26. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009, 361:1651-1661.
27. Anheim M, Elbaz A, Lesage S, Durr A, Condroyer C, Viallet F, et al. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 2012, 78(6):417-420.
28. Winder-Rhodes SE, Evans JR, Ban M, Mason SL, Williams-Gray CH, Foltynie T, et al. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain 2013, 136(2):392-399.
29. Gan-Or Z, Ozelius LJ, Bar-Shira A, Saunders-Pullman R, Mirelman A, Kornreich R, et al. The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease. Neurology 2013, 80(17):1606-1610.
30. Hill-Burns EM, Factor SA, Zabetian CP, Thomson G, Payami H Evidence for more than one Parkinson's disease-associated variant within the HLA region. PLoS One 2011, 6(11):e27109.